Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage…
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
April 19, 2026 19:45 ET | Source: Sutro Biopharma, Inc. STRO-004 demonstrates…
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS…
AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company…
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
April 13, 2026 09:00 ET | Source: Senti Biosciences, Inc. SOUTH SAN…
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring,…
